Storage and handling
STORAGE INFORMATION: KEEP TIGHTLY CLOSED. STORE AT 15°-25°C (59° -77°F).
STORAGE INFORMATION: KEEP TIGHTLY CLOSED. STORE AT 15°-25°C (59° -77°F).
STERILE - ANTIBACTERIAL
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Each gram contains bacitracin zinc 400 units, neomycin sulfate 5 mg (equiv. to 3.5 mg neomycin base), polymyxin B sulfate 10,000 units, in a base of white petrolatum and mineral oil.
INDICATIONS: For the treatment of superficial bacterial infections of the eyelid and conjunctiva in dogs and cats when due to organisms susceptible to the antibiotics contained in the ointment.
Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment.
DOSAGE AND ADMINISTRATION: Apply a thin film over the cornea three to four times daily in dogs and cats. The area should be properly cleansed prior to use. Foreign bodies, crusted exudates, and debris should be carefully removed prior to use.
WARNING: Do not use this product as a pre-surgical ocular lubricant. Adverse reactions of ocular irritation and corneal ulceration have been reported in association with such use.
Serious hypersensitivity (anaphylactic) reactions have been reported in cats within 4 hours of application of antibiotic ophthalmic preparations. Some of these reactions have resulted in death.
HUMAN WARNINGS: Keep out of reach of children.
PRECAUTIONS: Sensitivity to this ophthalmic ointment is rare, however, if a reaction occurs, discontinue use of the preparation. The prolonged use of antibiotic-containing preparations may result in overgrowth of nonsusceptible organisms including fungi.
Appropriate measures should be taken if this occurs.
If infection does not respond to treatment in two or three days, the diagnosis and therapy should be re-evaluated.
Care should be taken to not contaminate the applicator tip of the tube during the application of the preparation. Do not allow the applicator tip to come in contact with any tissue.
ADVERSE REACTIONS: Itching, burning or inflammation may occur in animals sensitive to the product. Discontinue use in such cases.
For a copy of the Safety Data Sheet (SDS), or to report adverse reactions, call Dechra Veterinary Products at (866) 933-2472.
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or
www.fda.gov/AnimalVeterinary/SafetyHealth
ACTIONS: The three antibiotics present in Vetropolycin (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment) Veterinary Ophthalmic Ointment provide a broad spectrum of activity against the gram-positive and gram-negative bacteria commonly involved in superficial infections of the eyelid and conjunctiva.
Bacitracin is effective against gram-positive bacteria including hemolytic and non-hemolytic streptococci and staphylococci.
Resistant strains rarely develop.
Neomycin is effective against both gram-positive and gram-negative bacteria including staphylococci, Escherichia coli and Haemophilus influenzae and many strains of Proteus and Pseudomonas.
Polymyxin B is bactericidal to gram-negative bacteria especially Pseudomonas. No resistant strains have been found to develop in vivo.
STORAGE INFORMATION: KEEP TIGHTLY CLOSED.
STORE AT 15°-25°C (59° -77°F).
HOW SUPPLIED: 3.5 g (1/8 oz) sterile tamper proof tubes.
NDC 17033-028-38
NADA 065-016, Approved by FDA
Manufactured for:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 USA
Rev. 03/18
Ini0912
Vetropolycin®
(neomycin and polymyxin B sulfates and bacitracin zinc
ophthalmic ointment) Veterinary Ophthalmic Ointment
STERILE - ANTIBACTERIAL
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
This product is not for use in food producing animals.
NADA 065-016, Approved by FDA
NET WT 3.5 g (1/8 oz)
Dechra

| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Bacitracin Zinc | ACTIVE INGREDIENT | 89Y4M234ES | 1 | |
| Neomycin Sulfate | ACTIVE INGREDIENT | 057Y626693 | 1 | |
| Polymyxin B Sulfate | ACTIVE INGREDIENT | 19371312D4 | 1 | |
| BACITRACIN | ACTIVE MOIETY | 58H6RWO52I | 1 | |
| NEOMYCIN | ACTIVE MOIETY | I16QD7X297 | 1 | |
| POLYMYXIN B | ACTIVE MOIETY | J2VZ07J96K | 1 | |
| mineral oil | INACTIVE INGREDIENT | T5L8T28FGP | 1 | |
| petrolatum | INACTIVE INGREDIENT | 4T6H12BN9U | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17033-028 | 17033-028-38 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Bacitracin Zinc | 89Y4M234ES | ACTIM |
| Neomycin Sulfate | 057Y626693 | ACTIM |
| Polymyxin B Sulfate | 19371312D4 | ACTIM |
| mineral oil | T5L8T28FGP | IACT |
| petrolatum | 4T6H12BN9U | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| mineral oil | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | LIQUID / RESPIRATORY (INHALATION) | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | TABLET, EXTENDED RELEASE / ORAL | 0.18 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / AURICULAR (OTIC) | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SPONGE / TOPICAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | AEROSOL, FOAM / TOPICAL | 7.9 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SOAP / TOPICAL | 0.85 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / TOPICAL | 7275 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CREAM / TOPICAL | 4213 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE / VAGINAL | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SUPPOSITORY / VAGINAL | 27 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / OPHTHALMIC | 88.4 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | TABLET / ORAL | 3.5 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT, AUGMENTED / TOPICAL | 81.94 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | LOTION / TOPICAL | 25 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | EMULSION / TOPICAL | 7.8 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CREAM, AUGMENTED / TOPICAL | 26 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / VAGINAL | 4084 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE, EXTENDED RELEASE / ORAL | 0.07 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Adverse event summaries are temporarily unavailable. Other product information remains available.